G. Dark

2.0k citations

28 papers · 1.4k indexed · 1 hit paper · h-index 14

Impact in

Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism
Oncology top 5%
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology

Papers in

Reproductive Medicine 8
- Ovarian cancer diagnosis and treatment 8
Oncology 12
- Cancer Treatment and Pharmacology 4
- Lung Cancer Research Studies 4

Co-authors: G. M. Tozer D J Chaplin S A Hill George R. Pettit Vivien E. Prise Ferry A.L.M. Eskens Dietmar W. Siemann Adam P. Dicker
Journals: Journal of Clinical Oncology (10 papers)Clinical Cancer Research (2 papers)Journal of Thoracic Oncology (2 papers)Lung Cancer (2 papers)Annals of Oncology (2 papers)
Partner nations: United Kingdom United States Belgium

In The Last Decade

G. Dark

28 papers receiving 1.4k citations

Hit Papers

align trajectories log scale

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. 1997 · 554 citations

Peers

Countries citing papers authored by G. Dark

Since Specialization

Citations

This map shows the geographic impact of G. Dark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Dark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Dark more than expected).

Fields of papers citing papers by G. Dark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Dark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Dark. The network helps show where G. Dark may publish in the future.

Co-authorship network

The 25 scholars most cited alongside G. Dark, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with G. Dark Line = papers co-authored together G. Dark links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer Gynecologic Oncology ·Gordon Rustin, Ignace Vergote, John P. Micha, Linda Duska, Nicholas Reed, Johanna C. Bendell, Daniel L. Spitz, G. Dark, Ute Hoch, Mary Tagliaferri, Alison L. Hannah, Agustin Garcia	2017	5
2	Impact of a 2-Week Oncology Placement on Medical Students’ Perception of Cancer Journal of Cancer Education ·Jonathan Mayes, Simon Davies, 仝杰英, Lily R. Wong, G. Dark	2016	8
3	Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer Journal of Clinical Oncology ·Ignace Vergote, Agustin A. García, John P. Micha, Charles H. Pippitt, Johanna C. Bendell, Daniel L. Spitz, Nicholas Reed, G. Dark, Paula M. Fracasso, Emad Ibrahim, Vincent Armenio, Linda Duska, Chris D. Poole, Christine Gennigens, Luc Dirix, Abraham C.F. Leung, Carol Zhao, Raoudha Soufi‐Mahjoubi, Gordon Rustin	2013	34
4	The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD). Journal of Clinical Oncology ·Agustin A. García, Ignace Vergote, John P. Micha, Charles H. Pippitt, Gautam G. Rao, Daniel L. Spitz, Gloria Carolina Fiallo Cardona, G. Dark, Magnus Jirlind, Vincent Armenio, Linda Duska, C. J. Poole, Christine Gennigens, Luc Dirix, Jeffrey West, Cheng Zhao, Ji-Eun Kim, Aimi Zafirah M. Yusof, Gordon Rustin	2011	4
5	Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program Journal of Thoracic Oncology ·Paul Taylor, B. Castagneto, G. Dark, M. Marangolo, Giorgio V. Scagliotti, Rob J. van Klaveren, Roberto Labianca, Monika Serke, Wolfgang Schuette, Jan P. van Meerbeeck, David F. Heigener, Lingzhi Li, Susumu Adachi, J. Blatter, Joachim von Pawel	2008	39
6	Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours Cancer Chemotherapy and Pharmacology ·Hugues Bourgeois, Jan B. Vermorken, G. Dark, Andrew Jones, P. Fumoleau, Roger Stupp, J.M. Tourani, Étienne Brain, Laurent Nguyen, Florence Lefresne, C. Puozzo	2007	32
7	Deconstructing the construction of a learning module on practice development European Journal of Cancer Care ·G. Dark, Rebecca M. Perrett	2007	2
8	C5-03: Open-label study of pemetrexed alone or in combination with a platinum for previously treated patients (pts) with malignant pleural mesothelioma (MPM): Outcomes from the International Expanded Access Program (EAP) Journal of Thoracic Oncology ·U. Gatzemeier, Paul Taylor, Joachim von Pawel, B. Castagneto, G. Dark, M. Marangolo, Rob J. van Klaveren, Jan P. van Meerbeeck, Susumu Adachi, J. Blatter	2007	2
9	Using e-learning as a tool for multidisciplinary education European Journal of Cancer Care ·G. Dark, Rebecca M. Perrett	2007	4
10	A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1) Annals of Oncology ·Richard Booton, Paul Lorigan, Heather Anderson, Sofia Baka, Linda Ashcroft, M. Nicolson, Mary Claire O’Brien, David J. Dunlop, Kenneth J. O’Byrne, E. Mechlová, M. Snee, G. Dark, N. Thatcher	2006	54
11	193 Vinflunine (VFL) in first line treatment of malignant pleural mesothelioma (MPM): Final results of a European phase II study Lung Cancer ·J. Margery, G Dabouis, G. Dark, H. G. Taylor, Kevin G. Harper, Joanna Rapcewicz, 黃椿煒黃椿煒, Denis Talbot	2006	3
12	Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group Journal of Clinical Oncology ·G. Dark, A H Calvert, Robert Grimshaw, Christopher Poole, K. Swenerton, Stan B. Kaye, Robert E. Coleman, Gordon C. Jayson, Tien Le, Susan Ellard, Marc Trudeau, P. Vasey, Marta Hamilton, T. Cameron, Emma Barrett, Wendy Walsh, L. McIntosh, Elizabeth A. Eisenhauer	2005	33
13	Interim results of the phase II study of vinflunine (VFL) in malignant pleural mesothelioma (MPM) Journal of Clinical Oncology ·Denis Talbot, J. Margery, Satriadi Trisnu, G. Dark, H. G. Taylor, Mara Mikaelly Santos da Silva, K. Ngongo, Joanna Rapcewicz, A. Riviére, Pierre Ruffiè	2005	4
14	Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial Clinical Cancer Research ·Giorgio V. Scagliotti, C. Kortsik, G. Dark, Allan Price, Christian Manegold, Rafael Rosell, Mary O’Brien, Patrick Peterson, Daniel Castellano, Giovanni Selvaggi, Silvia Novello, J. Blatter, L. Kayitalire, Lucio Crinò, Luis Paz‐Ares	2005	115
15	Proven bioequivalence of blood exposure between vinorelbine 80 mg/m² oral and 30 mg/m² IV doses in cancer patients Journal of Clinical Oncology ·Hugues Bourgeois, Jan B. Vermorken, G. Dark, Andrea A. Jones, P. Fumoleau, Roger Stupp, J.M. Tourani, D. Papadakis, Florence Lefresne, Laurent Nguyen	2005	127
16	Recent advances in mesothelioma Clinical Medicine ·G. Dark	2003	1
17	Emergencies in oncology Clinical Medicine ·G. Dark, Christina Thirlwell, Cathryn Brock	2003	3
18	Surveillance policy for stage I ovarian germ cell tumors. Journal of Clinical Oncology ·G. Dark, Mark Bower, E.S. Newlands, F.J. Paradinas, G.J.S. Rustin	1997	83
19	Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. PubMed ·G. Dark, S A Hill, Vivien E. Prise, G. M. Tozer, George R. Pettit, D J Chaplin Hit paper breakdown →	1997	554
20	Combretastatin A-4, an agent that displays selective toxicity towards tumour vasculature European Journal of Cancer ·D J Chaplin, Poulakis Nikolaos, G. M. Tozer, S Trembath-Reichert, G. Dark	1997	20

About G. Dark

G. Dark is a scholar working on Reproductive Medicine, Oncology, Pulmonary and Respiratory Medicine, Obstetrics and Gynecology and Genetics, having authored 28 papers that have together received 1.4k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (8 papers), Pleural and Pulmonary Diseases (5 papers), Occupational and environmental lung diseases (5 papers), Cancer Treatment and Pharmacology (4 papers), Lung Cancer Research Studies (4 papers), Angiogenesis and VEGF in Cancer (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers). The work is most often cited by research in Cancer Research (265 citations), Oncology (476 citations), Reproductive Medicine (134 citations), Toxicology (36 citations) and Pulmonary and Respiratory Medicine (334 citations). G. Dark has collaborated with scholars based in United Kingdom, United States and Belgium. Frequent co-authors include G. M. Tozer, D J Chaplin, S A Hill, George R. Pettit, Vivien E. Prise, Ferry A.L.M. Eskens, Dietmar W. Siemann, Adam P. Dicker, Michael C. Bibby and Patricia LoRusso. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Journal of Thoracic Oncology, Lung Cancer and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact